McKesson Corporation, with strong institutional ownership, continues to assert its position in the biotech market. It has declared continuous quarterly dividends over the years, consolidating its spot among
top value dividend stocks. The company recently completed the strategic acquisition of
PRISM Vision Holdings, strengthening its foothold in the vision healthcare sector. The acquisition aligns with McKesson's primary focus on
oncology and
biopharma growth. A series of robust financial results and
impressive earnings have resulted in solid growth of the company causing its shares to soar, touching
all-time highs. Financial commentators and experts, including
Jim Cramer, have continuously favored McKesson, often labelling it as a '
money machine'. The company's strategic divestiture of Canada-based Rexall and Well.ca supports their optimization efforts in more lucrative sectors such as oncology and biopharma. However, McKesson's third-quarter earnings fell below market expectations primarily due to supply-demand imbalances for weight-loss drugs.
Mckesson Corporation MCK News Analytics from Wed, 07 Aug 2024 07:00:00 GMT to Thu, 01 May 2025 19:15:57 GMT -
Rating 7
- Innovation 4
- Information 8
- Rumor 6
